Project Overview: Testing polycomb repressive complex 2 (PRC2) inhibitors in acute myeloid leukemia
Acute myeloid leukemia or AML is a type of cancer that is the result of abnormal division and development of blood cells. AML has very poor outcomes, with 5-year survival of less than 50 percent and even less in patients over the age of 60 [1]. Within AML, there are many subgroups that can dictate Read More …